Dr. Luk Mai Yee - Clinical Oncology
Specialist in Clinical Oncology
Highlights
- MCHK RegisteredVerified
- Specialist in Clinical OncologyBachelor of Medicine and Bachelor of Surgery (MBBS) · Hong Kong College of Radiologists · Medical degree 1992
- InsuranceBeing compiled｜See details
About
Dr. Luk Mai Yee is a registered Clinical Oncology specialist in Hong Kong.
Education
Specialist in Clinical Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)1992
Hong Kong Academy of Medicine fellowships
- FHKCRFellow, Hong Kong College of Radiologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Luk Mai Yee? Claim page and update insurance →
FAQ
Is Dr. Luk Mai Yee any good?
Dr. Luk Mai Yee is a registered Clinical Oncology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Luk Mai Yee do?
Dr. Luk Mai Yee practises in Clinical Oncology.
Are you Dr. Luk Mai Yee? Claim this page to update and manage.
ClaimResearch and publications
24 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis.Clinical breast cancer · 2026
- Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma: Systematic review and meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
- Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: Establishment of organs-at-risk constraints.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025
- Comparative study of the impact of adjuvant trastuzumab and its biosimilars on cardiac function in HER2-positive early breast cancer patients: a single-center study.Frontiers in oncology · 2025
- Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.Oral oncology · 2022
- Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant.Hepatology (Baltimore, Md.) · 2021
- The predictive value of G8 and the Cancer and aging research group chemotherapy toxicity tool in treatment-related toxicity in older Chinese patients with cancer.Journal of geriatric oncology · 2021
- Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases.Radiation oncology journal · 2021
- KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer.Clinical and translational medicine · 2021
- Repurposing hyperpolarization-activated cyclic nucleotide-gated channels as a novel therapy for breast cancer.Clinical and translational medicine · 2021
- Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.BMC infectious diseases · 2021
- Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review.Therapeutic advances in medical oncology · 2020
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer